Direxion Daily S&P Biotech Bull 3X ETF (LABU)

NYSEARCA: LABU · Real-Time Price · USD
276.16
+18.36 (7.12%)
Jun 26, 2026, 4:00 PM EDT - Market closed
7.12%
Assets $539.72M
Expense Ratio 0.96%
PE Ratio n/a
Shares Out 2.52M
Dividend (ttm) $1.01
Dividend Yield 0.37%
Ex-Dividend Date Dec 23, 2025
Payout Ratio n/a
1-Year Return +379.36%
Volume 767,206
Open 255.85
Previous Close 257.80
Day's Range 255.85 - 279.32
52-Week Low 55.12
52-Week High 279.32
Beta 2.48
Holdings 173
Inception Date May 28, 2015

About LABU

Fund Home Page

The Direxion Daily S&P Biotech Bull 3X ETF (LABU) is an exchange-traded fund that is based on the S&P Biotechnology Select Industry index. The fund provides daily 3 times exposure to the S&P Biotechnology Select Industry Index. LABU was launched on May 28, 2015 and is issued by Direxion.

Asset Class Equity
Category Trading--Leveraged Equity
Region North America
Stock Exchange NYSEARCA
Ticker Symbol LABU
ETF Provider Direxion
Index Tracked S&P Biotechnology Select Industry

Top 10 Holdings

73.63% of assets
Name Symbol Weight
Dreyfus Govt Cash Man Ins n/a 28.97%
Goldman Finl Sq Trsry Inst 506 n/a 11.37%
S&P Biotechnology Select Industry Index Swap n/a 8.50%
S&P Biotechnology Select Industry Index Swap n/a 6.41%
S&P Biotechnology Select Industry Index Swap n/a 4.99%
S&P Biotechnology Select Industry Index Swap n/a 4.21%
Goldman Sachs Fin Gov 465 Institut n/a 3.55%
S&P Biotechnology Select Industry Index Swap n/a 2.83%
S&P Biotechnology Select Industry Index Swap n/a 1.96%
Apogee Therapeutics, Inc. APGE 0.83%
View More Holdings

Dividends

Ex-Dividend Amount Pay Date
Dec 23, 2025 $0.90971 Dec 31, 2025
Sep 23, 2025 $0.10273 Sep 30, 2025
Jun 24, 2025 $0.21897 Jul 1, 2025
Mar 25, 2025 $0.10714 Apr 1, 2025
Jun 25, 2024 $0.15021 Jul 2, 2024
Mar 19, 2024 $0.16064 Mar 26, 2024
Full Dividend History

News

Where to Buy Booming Biotech ETFs

Discover why biotech stocks are surging despite large fund outflows. Monitor these three industry ETFs for "buy the dip" opportunities.

Other symbols: PBEXBI
7 years ago - Investopedia

Jablonski: Biotech presents a good buying opportunity

Sylvia Jablonski of Direxion discusses why biotech stocks and ETFs are attractive right now, due to their cheapness relative to the rest of the market.

Other symbols: CUREXLV
7 years ago - CNBC Television

Biotech stocks fall after Trump promises executive order drug prices

CNBC's Meg Tirrell reports on the dip in biotech stocks after President Donald Trump promised that an executive order on drug prices is coming.

7 years ago - CNBC Television